The effect of atazanavir and atazanavir/ritonavir on UDP- glucuronosyltransferase using lamotrigine as a phenotypic probe

Clinical Pharmacology and Therapeutics

Volumn 84, Issue 6, 2008, Pages 698-703

  Burger, D M ^a   Huisman, A ^a   Van Ewijk, N ^a   Neisingh, H ^a   Van Uden, P ^a   Rongen, G A ^a   Koopmans, P ^a   Bertz, R J ^b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; CETIRIZINE; GLUCURONOSYLTRANSFERASE; LAMOTRIGINE; RITONAVIR;

ADULT; ARTICLE; BILIRUBIN BLOOD LEVEL; BLOOD SAMPLING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG METABOLISM; DRUG SAFETY; DRUG WITHDRAWAL; ENZYME ACTIVITY; GLUCURONIDATION; HUMAN; HUMAN EXPERIMENT; LIVER FUNCTION TEST; LOW DRUG DOSE; MALE; NEUROTOXICITY; NORMAL HUMAN; PATIENT COMPLIANCE; PRIORITY JOURNAL; RASH; SIDE EFFECT; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT;

ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; CONFIDENCE INTERVALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; MOLECULAR PROBE TECHNIQUES; OLIGOPEPTIDES; PHENOTYPE; PROSPECTIVE STUDIES; PYRIDINES; REFERENCE VALUES; RITONAVIR; SENSITIVITY AND SPECIFICITY; TRIAZINES; YOUNG ADULT;

EID: 56549121559     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2008.106     Document Type: Article

References (26)

1. Boffito, M. et al. Therapeutic drug monitoring and drug-drug interactions involving antiretroviral drugs. Antivir. Ther. 10, 469-477 (2005).
2. Granfors, M.T., Wang, J.S., Kajosaari, L.I., Laitila, J., Neuvonen, P.J. & Backman, J.T. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol. 98, 79-85 (2006).
3. Aarnoutse, R.E. et al. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers. Clin. Pharmacol. Ther. 78, 664-674 (2005).
4. Yeh, R.F. et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J. Acquir. Immune Defic. Syndr. 42, 52-60 (2006).
5. Miners, J.O., Knights, K.M., Houston, J.B. & Mackenzie, P.I. In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem. Pharmacol. 71, 1531-1539 (2006).
6. Miners, J.O., Smith, P.A., Sorich, M.J., McKinnon, R.A. & Mackenzie, P.I. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu. Rev. Pharmacol. Toxicol. 44, 1-25 (2004).
7. Barbier, O. et al. 3′-azido-3′-deoxythimidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos. 28, 497-502 (2000).
8. Trapnell, C.B., Klecker, R.W., Jamis-Dow, C. & Collins, J.M. Glucuronidation of 3′-azido-3′-deoxythymidine (zidovudine) by human liver microsomes: relevance to clinical pharmacokinetic interactions with atovaquone, fluconazole, methadone, and valproic acid. Antimicrob. Agents Chemother. 42, 1592-1596 (1998).
9. Zhang, D., Chando, T.J., Everett, D.W., Patten, C.J., Dehal, S.S. & Humphreys, W.G. In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation. Drug Metab. Dispos. 33, 1729-1739 (2005).
10. Smith, C.M., Faucette, S.R., Wang, h. & LeCluyse, E.L. Modulation of UDP-glucuronosyltransferase 1A1 in primary human hepatocytes by prototypical inducers. J. Biochem. Mol. Toxicol. 19, 96-108 (2005).
11. Ouellet, D. et al. Effect of ritonavir on the pharmacokinetics of ethinyl oestradiol in healthy female volunteers. Br. J. Clin. Pharmacol. 46, 111-116 (1998).
12. Fichtenbaum, C.J. et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 16, 569-577 (2002).
13. Tseng, A.L. & Fletcher, D. Interaction between ritonavir and levothyroxine. AIDS 12, 2235-2236 (1998).
14. Van der Lee, M.J., et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin. Pharmacol. Ther. 80, 159-168 (2006).
15. Working Group of the office of AIDS Research Advisory Council (OARAC). Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, version 1, December 2007. 〈http://www.aidsinfo.nih.gov/ guidelines/〉. Accessed 26 January 2008.
16. Burger, D.M., Agarwala, S., Child, M., Been-Tiktak, A., Wang, Y., Bertz, & R. Effect of rifampin on steady-state pharmacokinetics of atazanavir with ritonavir in healthy volunteers. Antimicrob. Agents Chemother. 50, 3336-3342 (2006).
17. Kiang, T.K., Ensom, M.H. & Chang, T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol. Ther. 106, 97-132 (2005).
18. Waters, L.J. et al. Abacavir plasma pharmacokinetics in the absence and presence of atazanavir/ritonavir or lopinavir/ritonavir and vice versa in HIV-infected patients. Antivir. Ther. 12, 825-830 (2007).
19. Sidhu, J., Job, S., Singh, S. & Philipson, R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br. J. Clin. Pharmacol. 61, 191-199 (2006).
20. Christensen, J. et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia 48, 484-489 (2007).
21. Contin, M. et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia 47, 1573-1575 (2006).
22. Rowland, A., Elliot, D.J., Williams, J.A., Mackenzie, P.I., Dickinson, R.G. & Miners, J.O. In vitro characterization of lamotrigine N2-glucuronidation and the lamotrigine-valproic acid interaction. Drug Metab. Dispos. 34, 1055-1062 (2006).
23. Odishaw, J. & Chen, C. Effects of steady-state bupropion on the pharmacokinetics of lamotrigine in healthy subjects. Pharmacotherapy 20, 1448-1453 (2000).
24. L'homme, R.F., Dijkema, T., van der Ven, A.J. & Burger, D.M. Brief report: enzyme inducers reduce elimination half-life after a single dose of nevirapine in healthy women. J. Acquir. Immune Defic. Syndr. 43, 193-196 (2006).
25. Droste, J.A., Verweij-Van Wissen, C.P. & Burger, D.M. Simultaneous determination of the HIV drugs indinavir, amprenavir, saquinavir, ritonavir, lopinavir, nelfinavir, the nelfinavir hydroxymetabolite M8 and nevirapine in human plasma by reversed phase high performance liquid chromatography. Ther. Drug Monit. 25, 393-399 (2003).
26. US Department of Health and Human Services, Center for Drug Evaluation and Research, Food and Drug Administration. Guidance for Industry. Statistical approaches to establishing bioequivalence. 〈http://www.fda. gov/cder/guidance/index.htm〉. Accessed 10 August 2007.